Navigation Links
Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
Date:3/4/2013

FALLS CHURCH, Va., March 4, 2013 /PRNewswire/ -- One of the most critical challenges confronting the pharmaceutical industry is developing patient-friendly delivery systems for the growing biologics market, which currently totals $150 billion worldwide.  As the population ages, and the incidence rate of chronic indications rises globally, the market for biologics is expected to increase at a rate of nearly 10 percent annually. Biologic therapies typically require parenteral delivery due to their large size; however, injections are often painful for the patient, have a high risk of needle-stick injury, and require administration by a healthcare professional.  Consequently, there is a need to develop patient-friendly delivery methods for biologics that are convenient, safe, and increase patient compliance. Drug companies are actively seeking novel devices to make it easier for patients to self-administer drugs. By combining the drug formulation with a device, companies also have the opportunity to differentiate existing drugs as well as novel products in the pipeline.

Arina Paoli , Global Marketing Communications Manager for 3M, explains that the growing biologics market is driving the need for innovated delivery devices including microneedles. "We believe microneedle technologies will play a key role in the growth of the biologics market. We are seeing companies explore our MTS microneedle technologies to treat chronic conditions, such as rheumatoid arthritis, because this new delivery system has the potential to improve compliance and be easier to administer for both patients and caregivers," states Paoli.

To address these critical needs and identify business opportunities in this rapidly growing sector, Technology Catalysts International has launched a new Technology and Business Review on Next- Generation Self-Administered Drug-Device Combinations: New Technologies and Business Opportunities. This report focuses on the following leading delivery systems that will play a transformational role in optimizing delivery of biologics and promoting self-administration and enhanced patient compliance:

  • Autoinjectors and pen injectors
  • Prefilled syringes
  • Active transdermal devices, with a focus on microneedles
  • Inhalers

This report highlights the important regulatory approval process for drug-device combination products in the US, EU, and Japan. Important device design considerations, market trends, future applications, and challenges to developing drug-device combinations are also discussed. TCI's new report on Next-Generation Self-Administered Drug-Device Combinations will be made available online. Online features include:

  • Technology profiles updated in real time
  • A searchable database of technology profiles
  • Recent news on new product launches, licensing agreements, and collaborations

For complete report prospectus, pricing, and ordering information, please refer to:

http://www.technology-catalysts.com/reports_services/ddc.asp

About Technology Catalysts International:

Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research. The company specializes in technology licensing, technology assessment, and business intelligence with a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes. TCI is headquartered in the US and has offices in the UK, Germany, Czech Republic, China, Korea, Japan, India, and Latin America.

Contact:

Ajay Rastogi , Vice President
Technology Catalysts International
Telephone (703) 531-0257
arastogi@technology-catalysts.com
http://www.technology-catalysts.com


'/>"/>
SOURCE Technology Catalysts International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
2. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
3. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
4. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
5. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
6. MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
7. Remedy Informatics to Debut SpecimenTrack, Next-Generation Biorepository Software at ISBER 2012 Annual Meeting
8. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
9. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
10. HCG Injection Provider Posts Customer Testimonials on Ushcginjections.com Reviews Page
11. Nonin Medical Selected as Exclusive Provider of Cerebral/Somatic Oximetry Systems to Leading Pediatric Hospitals in Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
Breaking Medicine Technology:
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Getting enough sleep affects much more than energy ... going just 19 hours without sleep can compromise motor reaction time, which can increase the ... Amica Insurance is sharing the following tips from the NSF to help you sleep better ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... Patel M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is ... Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta ...
(Date:4/28/2017)... ... ... People are starting to accept that hearing aids can be helpful and are ... had when great-grandpa wore his hearing aids years ago,” said Dr. Maura Marks, founder ... Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid on his ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates ... leading ERP expert that specializes in long-term care, Brooke Grove now has the ...
Breaking Medicine News(10 mins):